论文部分内容阅读
为探究~(125)I标记重组抗蓖麻毒素(Ricin)人源化单克隆抗体(~(125)I-MIL50)在大鼠体内的药代动力学、生物分布及排泄特点,采用Iodogen法对MIL50进行~(125)I标记,结合TCA法测定不同时间~(125)IMIL50在大鼠血清、组织、体液和排泄物中的含量。结果表明:Ricin染毒组和直接给药组血药浓度在14d内没有差异,14d后染毒组~(125)I-MIL50消除快于未染毒组;血清中~(125)I-MIL50浓度高于其他组织和体液,肾、膀胱组织中浓度较高,脑、脊髓、脂肪等脂性组织中浓度一直较低;~(125)I-MIL50给药后27d内经尿累积排泄率约为62.6%,经粪便的排泄率为15.5%。研究结果为临床实验和给药方案提供参考依据。
In order to explore the pharmacokinetics, biodistribution and excretion of ~ (125) I-labeled recombinant human anti-Ricin monoclonal antibody (~ (125) I-MIL50) in rats, The levels of ~ (125) IMIL50 in serum, tissue, body fluid and excretion of rats at different time were determined by ~ (125) I labeling of MIL50 and TCA assay. The results showed that there was no difference in serum concentration of Ricin and direct administration groups within 14 days, and the level of 125 I-MIL50 in the treated group was faster than that of the non-exposed group after 14 days Concentrations were higher in adipose tissues such as brain, spinal cord and fat than those in other tissues and body fluids, and in kidney and bladder tissues. The cumulative rate of excretion of urine during 27 days after administration of ~ (125) I-MIL50 was about 62.6 %, The excretion rate of excretion was 15.5%. The results provide a reference for clinical trials and drug delivery programs.